Myriad receives reimbursement for the BRACAnalysis Diagnostic System in Japan

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Myriad Genetics has received reimbursement and launched the BRACAnalysis Diagnostic System in Japan to help physicians determine which people affected with breast and ovarian cancer have hereditary breast and ovarian cancer syndrome and qualify for additional diagnostic and medical management.

BRACAnalysis was approved by Japan’s Ministry of Health, Labour and Welfare in November 2019 for this indication.

Table of Contents

YOU MAY BE INTERESTED IN

Members of the National Cancer Advisory Board’s ad hoc Working Group on Extramural Research Concepts and Programs at a recent meeting struggled to define the new group’s the role and raised concerns about some initial growing pains.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login